NCT07323576 2026-02-09
INAVO-CRC
Hoffmann-La Roche
Phase 2 Withdrawn
Clinical Trials
40 trialsNCT06106308 2026-01-12
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Cardiff Oncology
Phase 2 Active not recruiting
NCT04595266 2025-09-29
LIVERPEARL
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Active not recruiting
NCT05480306 2025-08-03
DeFianCe
Leap Therapeutics, Inc.
Phase 2 Completed
NCT03186326 2025-06-29
SAMCO
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT03584711 2025-06-29
OPTIPRIME
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT06991465 2025-05-28
Hypo-OPRA
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 2 Recruiting
NCT06907342 2025-05-25
COSENSE-1
St. Olavs Hospital
Phase 2 Recruiting
NCT06225843 2025-02-19
EGIA-003
Alethia Biotherapeutics
Phase 2 Recruiting
NCT06475352 2025-01-27
FUDOSE
UNICANCER
Phase 2 Recruiting
NCT05039944 2024-07-18
SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Terminated
NCT06218810 2024-01-23
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer
Fudan University
Phase 2 Recruiting
NCT01622543 2023-08-23
Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT05797883 2023-04-04
FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer
China Medical University, China
Phase 2 Unknown
NCT00066274 2021-03-02
Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
UNICANCER
Phase 2 Completed
NCT00006050 2021-02-17
Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
UNICANCER
Phase 2 Completed
NCT01417494 2020-11-03
1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT01363843 2020-06-11
Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)
Brown University
Phase 2 Completed
NCT00613080 2018-09-25
Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00551213 2018-08-24
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01288339 2018-05-16
PULSE
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Completed
NCT03377842 2017-12-19
Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer
Sichuan Provincial People's Hospital
Phase 2 Unknown
NCT01418222 2017-05-30
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Genentech, Inc.
Phase 2 Completed
NCT02202928 2015-12-28
Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer
Shenzhen Hornetcorn Bio-technology Company, LTD
Phase 2 Unknown
NCT00890305 2015-07-08
Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone
Medivation, Inc.
Phase 2 Completed
NCT00959647 2015-01-07
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
Phase 2 Completed
NCT02128425 2014-05-07
FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT00016198 2013-06-26
Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00103298 2013-06-20
Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025142 2013-05-15
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00615056 2013-04-19
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
Pfizer
Phase 2 Completed
NCT00202787 2013-02-20
Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 2 Completed
NCT00016978 2013-02-05
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan
National Cancer Institute (NCI)
Phase 2 Completed
NCT00043004 2012-09-24
Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT00866944 2011-11-11
MT201-204
Amgen Research (Munich) GmbH
Phase 2 Completed
NCT00004102 2011-03-28
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
NYU Langone Health
Phase 2 Completed
NCT00813137 2009-12-08
FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer
Simcere Pharmaceutical Co., Ltd
Phase 2 Unknown
NCT00884767 2009-07-08
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00006115 2009-01-13
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00116506 2007-12-21
Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed